UPDATE: Viracta Therapeutics Announces 'Promising data show complete responses observed across multiple subtypes of Epstein-Barr virus positive (EBV+) lymphoma; preliminary ORR/CR of 80%/40% in T/NK-NHL and 66%/33% in DLBCL'